Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Верапамил замедленного высвобождения: возможности применения в клинической практике - Журнал Системные Гипертензии Том 13, №3
Верапамил замедленного высвобождения: возможности применения в клинической практике
Гапонова Н.И., Абдрахманов В.Р. Верапамил замедленного высвобождения: возможности применения в клинической практике. Системные гипертензии. 2016; 13 (3): 64–68.
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
В обзоре отражены результаты применения верапамила (препарат Изоптин® СР) пролонгированного действия в клинической практике. Многочисленные рандомизированные клинические исследования подтверждают высокую эффективность и безопасность применения препарата Изоптин® СР при артериальной гипертонии, а также у пациентов с артериальной гипертонией в сочетании с ишемической болезнью сердца, хроническими обструктивными заболеваниями легких, нарушениями углеводного и липидного обмена. Доказано преимущество применения препарата Изоптин® СР (верапамил) при наджелудочковых нарушениях сердечного ритма.
Ключевые слова: артериальная гипертония, блокаторы кальциевых каналов, верапамил, Изоптин® СР замедленного высвобождения.
Key words: arterial hypertension, calcium channel blockers, verapamil, Isoptin® SR prolonged-release tablets.
Ключевые слова: артериальная гипертония, блокаторы кальциевых каналов, верапамил, Изоптин® СР замедленного высвобождения.
________________________________________________
Key words: arterial hypertension, calcium channel blockers, verapamil, Isoptin® SR prolonged-release tablets.
Полный текст
Список литературы
1. Чазова И.Е., Жернакова Ю.В. Блокаторы кальциевых каналов: более 50 лет на страже здоровья. Системные гипертензии. 2015; 12 (12): 49–56. / Chazova I.E., Zhernakova Iu.V. Blokatory kal'tsievykh kanalov: bolee 50 let na strazhe zdorov'ia. Systemic Hypertension. 2015; 12 (12): 49–56. [in Russian]
2. Furberg CD, Psaty BM, Meyer JV. Nifedipine: Dose-related increase in mortality in patients with coronary heart disease. Circulation 1995; 92 (5): 1326–31.
3. Lee SH, Yu WC, Cheng JJ et al. Effect of verapamil on long-term tachycardia – induced atrial electrical remodeling. Circulation 2000; 101: 200–6.
4. Leistad E, Alknes G, Verburg E et al. Atrial contractile dysfunction after short-term atrial fibrillation is reduced by verapamil but increased by BAY K 8644. Circulation 1996; 93: 1736–54.
5. Lefrandt JD, Heitmann J, Sevre K et al. The effects of dihydropyridine and phenylalkylamine calcium antagonist classes on autonomic function in hypertension: the VAMPHYRE study. Am J Hypertens 2001; 14: 1083–9.
6. Harris DCH, Hammond WS, Bure TJ et al. Verapamil protects against progression of experimental chronic renal failure. Kidney Int 1987; 31: 41–6.
7. Bacris GZ, Copley JB, Vicknair N et al. Verapamil SR has similar nephroprotective properties to lisinopril and is significantly better in comparison to atenolol. Kidney International 1996; 50: 1641–59.
8. Stadler P, Leonardi L, Riesen W et al. Cardiovascular effects of verapamil in essential hypertension. Clin Pharmacol Ther 1987; 42: 485–92.
9. Speders S, Sosna J, Schumacher A et al. Efficacy and tolerability of Isoptin SR in essential hypertension. Hochdruck 1988; 8: 3–14.
10. EVEREST’H – Evaluation of Verapamil for Efficacy, Safety and Tolerability in the management of Hypertension. Multicentre trial of the antihypertensive efficacy and safety of Verapamil SR. Act Med Int 1990; 2: 3–7.
11. Кукес В.Г., Красных Л.М., Теплоногова Е.В. Применение Изоптина SR в лечении артериальной гипертонии. Клин. фармакология и терапия. 1999; 8: 51–2. / Kukes V.G., Krasnykh L.M., Teplonogova E.V. Primenenie Izoptina SR v lechenii arterial'noi gipertonii. Klin. farmakologiia i terapiia. 1999; 8: 51–2. [in Russian]
12. Grossman E, Messerli FH. Effect of calcium antagonists on plasma norepinerhrine levels, heart rate and blood pressure. Am J Cardiol 1997; 80: 1453–8.
13. Zachariah P, Sheps S, Oshrain C et al. Antihypertensive efficacy of sustained-release verapamil. J Clin Hypertens 1987; 3: 536–46.
14. Speders S, Sosna J, Schumacher A et al. Efficacy and safety of verapamil SR 240 mg in essential hypertension: results of a multicentric phase IV study. J Cardiovasc Pharmacol 1989; 13 (Suppl. 4): S.47–S.49.
15. Cummings JM, Amadlio P, Nelson L. The role of calcium channel blocker in the treatment of essential hypertension. Arch Intern Med 1991; 151: 250–9.
16. Маколкин В.И. Изоптин СР 240 – эффективный антигипертензивный и антиишемический препарат. Артериальная гипертензия. 2006; 3: 233–6. / Makolkin V.I. Izoptin SR 240 – effektivnyi antigipertenzivnyi i antiishemicheskii preparat. Arterial'naia gipertenziia. 2006; 3: 233–6. [in Russian]
17. Hla K, Henry J, Latham A. Pharmacokinetics and pharmacodynamics of two formulations of verapamil. Br J Clin Pharmacol 1987; 24: 661–4.
18. Weinberger MH. The relationship of sodium balance and concomitant diuretic therapy to blood pressure response with calcium channel entry blockers. Am J Med 1991; 90 (Suppl. 5A): S.15–S.20.
19. Weir M, Lavin P. Comparison of the efficacy and tolerability of lisinopril and sustained – release verapamil in older patients with hypertension. Clin Ther 1991; 13 (3): 401–8.
20. Rubio-Guerra AF, Vargas-Robles H, Vargas-Ayala G et al. The effect of trandolapril and its fixed-dose combination with verapamil on circulating adhesion molecules levels in hypertensive patients with type 2 diabetes. Clin Exp Hypertens 2008; 30 (7): 685–8.
21. Манукян А.В., Сидоренкова Н.Б., Лаврентьев А.В. Влияние пролонгированных антагонистов кальция на циркадианный и ультрадианный ритмы артериального давления больных с артериальной гипертонией высокого риска. Фармакология. 2006; 7 (9): 228–35. / Manukian A.V., Sidorenkova N.B., Lavrent'ev A.V. Vliianie prolongirovannykh antagonistov kal'tsiia na tsirkadiannyi i ul'tradiannyi ritmy arterial'nogo davleniia bol'nykh s arterial'noi gipertoniei vysokogo riska. Farmakologiia. 2006; 7 (9): 228–35. [in Russian]
22. Schmieder RE, Messerli FH, Garavaglia GE et al. Cardiovascular effects of verapamil in patients with essential hypertension. Circulation 1987; 75 (5): 1030–6.
23. Granier P, Douste-Blazy M, Tredez P et al. Improvement in left ventricular hypertrophy and left ventricular diastolic function following verapamil therapy in mild to moderate hypertension. Eur J Clin Pharmacol 1990; 39 (Suppl. 1): S.45–S.46.
24. Van Merode T, Van Bortel L, Smeets FA et al. The effect of verapamil on carotid artery distensability and cross-sectional compliance in hypertensive patients. J Cardiovase Pharmacol 1990; 1: 109–13.
25. Breithaupt-Grogler K, Gerhardt G, Lehmann G et al. Blood pressure and aortic elastic properties-verapamil SR/trandolapril compared a metoprolol/hydrochlorothiazide combination therapy. Int J Clin Pharm Ther 1998; 36: 425–31.
26. Ferrari R, Cuchtnt K, Bobgneti R et al. How do calcium antagonists differ in clinical practice? Cardiovasc Drug Therapy 1994; 8 (Suppl. 3): S.566–S.575.
27. Pepine C, Handberg E, Cooper-De-Hoff R et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): A Randomized Controlled Trial. JAMA 2003; 290: 2805–16.
28. Pallone NM. Effect of calcium antagonists in the treatment of silent ischemic heart disease. Curr Ther Res 1989; 45: 339–46.
29. Rehnqvist N, Hjemdahl P, Billing E et al. Effect of metoprolol vs verapamil in patients with stable angina pectoris. The Angina Prognosis Study in Stockholm (APSIS). Eur Heart J 1996; 17: 76–81.
30. The Danish Verapamil Infarction Trial II – DAVIT II: Effect of verapamil on mortality and maior events after acute myocardial infarction. Am J Cardiol 1990; 66: 331–401.
31. Rengo F, Carbonin P, Pahor M et al. A controlled Trial of verapamil inpatients after acute myocardial infarction: results of the Calcium Antagonist Reinfarction Italian Study (CRIS). Am J Cardiol 1996; 77: 365–9.
32. Hoberg E, Dietz R, Frees U et al. Verapamil treatment after coronary angioplasty in patients at high risk of recurrent stenosis. Br Heart J 1994; 71: 254–60.
33. Задионченко В.С., Адашева Т.В., Жилова Е.В. и соавт. Клинико-функциональные особенности артериальной гипертонии у больных хроническим обструктивным заболеванием легких. РМЖ. 2003; 9: 535–8. / Zadionchenko V.S., Adasheva T.V., Zhilova E.V. i soavt. Kliniko-funktsional'nye osobennosti arterial'noi gipertonii u bol'nykh khronicheskim obstruktivnym zabolevaniem legkikh. RMZh. 2003; 9: 535–8. [in Russian]
34. Дворецкий Л.И. Клинические рекомендации по ведению больных ХОБЛ в сочетании с артериальной гипертонией и другой патологией. РМЖ. 2005; 13: 672–5. / Dvoretskii L.I. Klinicheskie rekomendatsii po vedeniiu bol'nykh KhOBL v sochetanii s arterial'noi gipertoniei i drugoi patologiei. RMZh. 2005; 13: 672–5. [in Russian]
35. Карпов Ю.А., Сорокин Е.В. Особенности лечения артериальной гипертонии при хронических обструктивных заболеваниях легких. РМЖ. 2003; 19: 1048–51. / Karpov Iu.A., Sorokin E.V. Osobennosti lecheniia arterial'noi gipertonii pri khronicheskikh obstruktivnykh zabolevaniiakh legkikh. RMZh. 2003; 19: 1048–51. [in Russian]
36. Andersson D, Rojdmark S. Improvement of glucose tolerance by verapamil in patients with non-insulin-dependent diabetes mellitus. Acta Med Scand 1981; 210 (1–2): 27–33.
37. Libretti A, Catalano M. Lipid profile during antihypertensive treatment. The SLIP Study Group: Study on Lipids with Isoptin Press. Drugs 1993; 46 (Suppl. 2): S.16–S.23.
38. Rosei E, Dal Palu C, Leonetti G et al. Clinical results of the Verapamil in Hypertension and Atherosclerosis Study (VHAS). J Hypertension 1997; 15: 1337–44.
39. Echizen H, Eichelbaum M. Clinical Pharmacokinetics of verapamil, nifedipine and diltiazem. Clin Pharmacokinetics 1986; 11: 425–49.
2. Furberg CD, Psaty BM, Meyer JV. Nifedipine: Dose-related increase in mortality in patients with coronary heart disease. Circulation 1995; 92 (5): 1326–31.
3. Lee SH, Yu WC, Cheng JJ et al. Effect of verapamil on long-term tachycardia – induced atrial electrical remodeling. Circulation 2000; 101: 200–6.
4. Leistad E, Alknes G, Verburg E et al. Atrial contractile dysfunction after short-term atrial fibrillation is reduced by verapamil but increased by BAY K 8644. Circulation 1996; 93: 1736–54.
5. Lefrandt JD, Heitmann J, Sevre K et al. The effects of dihydropyridine and phenylalkylamine calcium antagonist classes on autonomic function in hypertension: the VAMPHYRE study. Am J Hypertens 2001; 14: 1083–9.
6. Harris DCH, Hammond WS, Bure TJ et al. Verapamil protects against progression of experimental chronic renal failure. Kidney Int 1987; 31: 41–6.
7. Bacris GZ, Copley JB, Vicknair N et al. Verapamil SR has similar nephroprotective properties to lisinopril and is significantly better in comparison to atenolol. Kidney International 1996; 50: 1641–59.
8. Stadler P, Leonardi L, Riesen W et al. Cardiovascular effects of verapamil in essential hypertension. Clin Pharmacol Ther 1987; 42: 485–92.
9. Speders S, Sosna J, Schumacher A et al. Efficacy and tolerability of Isoptin SR in essential hypertension. Hochdruck 1988; 8: 3–14.
10. EVEREST’H – Evaluation of Verapamil for Efficacy, Safety and Tolerability in the management of Hypertension. Multicentre trial of the antihypertensive efficacy and safety of Verapamil SR. Act Med Int 1990; 2: 3–7.
11. Kukes V.G., Krasnykh L.M., Teplonogova E.V. Primenenie Izoptina SR v lechenii arterial'noi gipertonii. Klin. farmakologiia i terapiia. 1999; 8: 51–2. [in Russian]
12. Grossman E, Messerli FH. Effect of calcium antagonists on plasma norepinerhrine levels, heart rate and blood pressure. Am J Cardiol 1997; 80: 1453–8.
13. Zachariah P, Sheps S, Oshrain C et al. Antihypertensive efficacy of sustained-release verapamil. J Clin Hypertens 1987; 3: 536–46.
14. Speders S, Sosna J, Schumacher A et al. Efficacy and safety of verapamil SR 240 mg in essential hypertension: results of a multicentric phase IV study. J Cardiovasc Pharmacol 1989; 13 (Suppl. 4): S.47–S.49.
15. Cummings JM, Amadlio P, Nelson L. The role of calcium channel blocker in the treatment of essential hypertension. Arch Intern Med 1991; 151: 250–9.
16. Makolkin V.I. Izoptin SR 240 – effektivnyi antigipertenzivnyi i antiishemicheskii preparat. Arterial'naia gipertenziia. 2006; 3: 233–6. [in Russian]
17. Hla K, Henry J, Latham A. Pharmacokinetics and pharmacodynamics of two formulations of verapamil. Br J Clin Pharmacol 1987; 24: 661–4.
18. Weinberger MH. The relationship of sodium balance and concomitant diuretic therapy to blood pressure response with calcium channel entry blockers. Am J Med 1991; 90 (Suppl. 5A): S.15–S.20.
19. Weir M, Lavin P. Comparison of the efficacy and tolerability of lisinopril and sustained – release verapamil in older patients with hypertension. Clin Ther 1991; 13 (3): 401–8.
20. Rubio-Guerra AF, Vargas-Robles H, Vargas-Ayala G et al. The effect of trandolapril and its fixed-dose combination with verapamil on circulating adhesion molecules levels in hypertensive patients with type 2 diabetes. Clin Exp Hypertens 2008; 30 (7): 685–8.
21. Manukian A.V., Sidorenkova N.B., Lavrent'ev A.V. Vliianie prolongirovannykh antagonistov kal'tsiia na tsirkadiannyi i ul'tradiannyi ritmy arterial'nogo davleniia bol'nykh s arterial'noi gipertoniei vysokogo riska. Farmakologiia. 2006; 7 (9): 228–35. [in Russian]
22. Schmieder RE, Messerli FH, Garavaglia GE et al. Cardiovascular effects of verapamil in patients with essential hypertension. Circulation 1987; 75 (5): 1030–6.
23. Granier P, Douste-Blazy M, Tredez P et al. Improvement in left ventricular hypertrophy and left ventricular diastolic function following verapamil therapy in mild to moderate hypertension. Eur J Clin Pharmacol 1990; 39 (Suppl. 1): S.45–S.46.
24. Van Merode T, Van Bortel L, Smeets FA et al. The effect of verapamil on carotid artery distensability and cross-sectional compliance in hypertensive patients. J Cardiovase Pharmacol 1990; 1: 109–13.
25. Breithaupt-Grogler K, Gerhardt G, Lehmann G et al. Blood pressure and aortic elastic properties-verapamil SR/trandolapril compared a metoprolol/hydrochlorothiazide combination therapy. Int J Clin Pharm Ther 1998; 36: 425–31.
26. Ferrari R, Cuchtnt K, Bobgneti R et al. How do calcium antagonists differ in clinical practice? Cardiovasc Drug Therapy 1994; 8 (Suppl. 3): S.566–S.575.
27. Pepine C, Handberg E, Cooper-De-Hoff R et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): A Randomized Controlled Trial. JAMA 2003; 290: 2805–16.
28. Pallone NM. Effect of calcium antagonists in the treatment of silent ischemic heart disease. Curr Ther Res 1989; 45: 339–46.
29. Rehnqvist N, Hjemdahl P, Billing E et al. Effect of metoprolol vs verapamil in patients with stable angina pectoris. The Angina Prognosis Study in Stockholm (APSIS). Eur Heart J 1996; 17: 76–81.
30. The Danish Verapamil Infarction Trial II – DAVIT II: Effect of verapamil on mortality and maior events after acute myocardial infarction. Am J Cardiol 1990; 66: 331–401.
31. Rengo F, Carbonin P, Pahor M et al. A controlled Trial of verapamil inpatients after acute myocardial infarction: results of the Calcium Antagonist Reinfarction Italian Study (CRIS). Am J Cardiol 1996; 77: 365–9.
32. Hoberg E, Dietz R, Frees U et al. Verapamil treatment after coronary angioplasty in patients at high risk of recurrent stenosis. Br Heart J 1994; 71: 254–60.
33. Zadionchenko V.S., Adasheva T.V., Zhilova E.V. i soavt. Kliniko-funktsional'nye osobennosti arterial'noi gipertonii u bol'nykh khronicheskim obstruktivnym zabolevaniem legkikh. RMZh. 2003; 9: 535–8. [in Russian]
34. Dvoretskii L.I. Klinicheskie rekomendatsii po vedeniiu bol'nykh KhOBL v sochetanii s arterial'noi gipertoniei i drugoi patologiei. RMZh. 2005; 13: 672–5. [in Russian]
35. Karpov Iu.A., Sorokin E.V. Osobennosti lecheniia arterial'noi gipertonii pri khronicheskikh obstruktivnykh zabolevaniiakh legkikh. RMZh. 2003; 19: 1048–51. [in Russian]
36. Andersson D, Rojdmark S. Improvement of glucose tolerance by verapamil in patients with non-insulin-dependent diabetes mellitus. Acta Med Scand 1981; 210 (1–2): 27–33.
37. Libretti A, Catalano M. Lipid profile during antihypertensive treatment. The SLIP Study Group: Study on Lipids with Isoptin Press. Drugs 1993; 46 (Suppl. 2): S.16–S.23.
38. Rosei E, Dal Palu C, Leonetti G et al. Clinical results of the Verapamil in Hypertension and Atherosclerosis Study (VHAS). J Hypertension 1997; 15: 1337–44.
39. Echizen H, Eichelbaum M. Clinical Pharmacokinetics of verapamil, nifedipine and diltiazem. Clin Pharmacokinetics 1986; 11: 425–49.
2. Furberg CD, Psaty BM, Meyer JV. Nifedipine: Dose-related increase in mortality in patients with coronary heart disease. Circulation 1995; 92 (5): 1326–31.
3. Lee SH, Yu WC, Cheng JJ et al. Effect of verapamil on long-term tachycardia – induced atrial electrical remodeling. Circulation 2000; 101: 200–6.
4. Leistad E, Alknes G, Verburg E et al. Atrial contractile dysfunction after short-term atrial fibrillation is reduced by verapamil but increased by BAY K 8644. Circulation 1996; 93: 1736–54.
5. Lefrandt JD, Heitmann J, Sevre K et al. The effects of dihydropyridine and phenylalkylamine calcium antagonist classes on autonomic function in hypertension: the VAMPHYRE study. Am J Hypertens 2001; 14: 1083–9.
6. Harris DCH, Hammond WS, Bure TJ et al. Verapamil protects against progression of experimental chronic renal failure. Kidney Int 1987; 31: 41–6.
7. Bacris GZ, Copley JB, Vicknair N et al. Verapamil SR has similar nephroprotective properties to lisinopril and is significantly better in comparison to atenolol. Kidney International 1996; 50: 1641–59.
8. Stadler P, Leonardi L, Riesen W et al. Cardiovascular effects of verapamil in essential hypertension. Clin Pharmacol Ther 1987; 42: 485–92.
9. Speders S, Sosna J, Schumacher A et al. Efficacy and tolerability of Isoptin SR in essential hypertension. Hochdruck 1988; 8: 3–14.
10. EVEREST’H – Evaluation of Verapamil for Efficacy, Safety and Tolerability in the management of Hypertension. Multicentre trial of the antihypertensive efficacy and safety of Verapamil SR. Act Med Int 1990; 2: 3–7.
11. Кукес В.Г., Красных Л.М., Теплоногова Е.В. Применение Изоптина SR в лечении артериальной гипертонии. Клин. фармакология и терапия. 1999; 8: 51–2. / Kukes V.G., Krasnykh L.M., Teplonogova E.V. Primenenie Izoptina SR v lechenii arterial'noi gipertonii. Klin. farmakologiia i terapiia. 1999; 8: 51–2. [in Russian]
12. Grossman E, Messerli FH. Effect of calcium antagonists on plasma norepinerhrine levels, heart rate and blood pressure. Am J Cardiol 1997; 80: 1453–8.
13. Zachariah P, Sheps S, Oshrain C et al. Antihypertensive efficacy of sustained-release verapamil. J Clin Hypertens 1987; 3: 536–46.
14. Speders S, Sosna J, Schumacher A et al. Efficacy and safety of verapamil SR 240 mg in essential hypertension: results of a multicentric phase IV study. J Cardiovasc Pharmacol 1989; 13 (Suppl. 4): S.47–S.49.
15. Cummings JM, Amadlio P, Nelson L. The role of calcium channel blocker in the treatment of essential hypertension. Arch Intern Med 1991; 151: 250–9.
16. Маколкин В.И. Изоптин СР 240 – эффективный антигипертензивный и антиишемический препарат. Артериальная гипертензия. 2006; 3: 233–6. / Makolkin V.I. Izoptin SR 240 – effektivnyi antigipertenzivnyi i antiishemicheskii preparat. Arterial'naia gipertenziia. 2006; 3: 233–6. [in Russian]
17. Hla K, Henry J, Latham A. Pharmacokinetics and pharmacodynamics of two formulations of verapamil. Br J Clin Pharmacol 1987; 24: 661–4.
18. Weinberger MH. The relationship of sodium balance and concomitant diuretic therapy to blood pressure response with calcium channel entry blockers. Am J Med 1991; 90 (Suppl. 5A): S.15–S.20.
19. Weir M, Lavin P. Comparison of the efficacy and tolerability of lisinopril and sustained – release verapamil in older patients with hypertension. Clin Ther 1991; 13 (3): 401–8.
20. Rubio-Guerra AF, Vargas-Robles H, Vargas-Ayala G et al. The effect of trandolapril and its fixed-dose combination with verapamil on circulating adhesion molecules levels in hypertensive patients with type 2 diabetes. Clin Exp Hypertens 2008; 30 (7): 685–8.
21. Манукян А.В., Сидоренкова Н.Б., Лаврентьев А.В. Влияние пролонгированных антагонистов кальция на циркадианный и ультрадианный ритмы артериального давления больных с артериальной гипертонией высокого риска. Фармакология. 2006; 7 (9): 228–35. / Manukian A.V., Sidorenkova N.B., Lavrent'ev A.V. Vliianie prolongirovannykh antagonistov kal'tsiia na tsirkadiannyi i ul'tradiannyi ritmy arterial'nogo davleniia bol'nykh s arterial'noi gipertoniei vysokogo riska. Farmakologiia. 2006; 7 (9): 228–35. [in Russian]
22. Schmieder RE, Messerli FH, Garavaglia GE et al. Cardiovascular effects of verapamil in patients with essential hypertension. Circulation 1987; 75 (5): 1030–6.
23. Granier P, Douste-Blazy M, Tredez P et al. Improvement in left ventricular hypertrophy and left ventricular diastolic function following verapamil therapy in mild to moderate hypertension. Eur J Clin Pharmacol 1990; 39 (Suppl. 1): S.45–S.46.
24. Van Merode T, Van Bortel L, Smeets FA et al. The effect of verapamil on carotid artery distensability and cross-sectional compliance in hypertensive patients. J Cardiovase Pharmacol 1990; 1: 109–13.
25. Breithaupt-Grogler K, Gerhardt G, Lehmann G et al. Blood pressure and aortic elastic properties-verapamil SR/trandolapril compared a metoprolol/hydrochlorothiazide combination therapy. Int J Clin Pharm Ther 1998; 36: 425–31.
26. Ferrari R, Cuchtnt K, Bobgneti R et al. How do calcium antagonists differ in clinical practice? Cardiovasc Drug Therapy 1994; 8 (Suppl. 3): S.566–S.575.
27. Pepine C, Handberg E, Cooper-De-Hoff R et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): A Randomized Controlled Trial. JAMA 2003; 290: 2805–16.
28. Pallone NM. Effect of calcium antagonists in the treatment of silent ischemic heart disease. Curr Ther Res 1989; 45: 339–46.
29. Rehnqvist N, Hjemdahl P, Billing E et al. Effect of metoprolol vs verapamil in patients with stable angina pectoris. The Angina Prognosis Study in Stockholm (APSIS). Eur Heart J 1996; 17: 76–81.
30. The Danish Verapamil Infarction Trial II – DAVIT II: Effect of verapamil on mortality and maior events after acute myocardial infarction. Am J Cardiol 1990; 66: 331–401.
31. Rengo F, Carbonin P, Pahor M et al. A controlled Trial of verapamil inpatients after acute myocardial infarction: results of the Calcium Antagonist Reinfarction Italian Study (CRIS). Am J Cardiol 1996; 77: 365–9.
32. Hoberg E, Dietz R, Frees U et al. Verapamil treatment after coronary angioplasty in patients at high risk of recurrent stenosis. Br Heart J 1994; 71: 254–60.
33. Задионченко В.С., Адашева Т.В., Жилова Е.В. и соавт. Клинико-функциональные особенности артериальной гипертонии у больных хроническим обструктивным заболеванием легких. РМЖ. 2003; 9: 535–8. / Zadionchenko V.S., Adasheva T.V., Zhilova E.V. i soavt. Kliniko-funktsional'nye osobennosti arterial'noi gipertonii u bol'nykh khronicheskim obstruktivnym zabolevaniem legkikh. RMZh. 2003; 9: 535–8. [in Russian]
34. Дворецкий Л.И. Клинические рекомендации по ведению больных ХОБЛ в сочетании с артериальной гипертонией и другой патологией. РМЖ. 2005; 13: 672–5. / Dvoretskii L.I. Klinicheskie rekomendatsii po vedeniiu bol'nykh KhOBL v sochetanii s arterial'noi gipertoniei i drugoi patologiei. RMZh. 2005; 13: 672–5. [in Russian]
35. Карпов Ю.А., Сорокин Е.В. Особенности лечения артериальной гипертонии при хронических обструктивных заболеваниях легких. РМЖ. 2003; 19: 1048–51. / Karpov Iu.A., Sorokin E.V. Osobennosti lecheniia arterial'noi gipertonii pri khronicheskikh obstruktivnykh zabolevaniiakh legkikh. RMZh. 2003; 19: 1048–51. [in Russian]
36. Andersson D, Rojdmark S. Improvement of glucose tolerance by verapamil in patients with non-insulin-dependent diabetes mellitus. Acta Med Scand 1981; 210 (1–2): 27–33.
37. Libretti A, Catalano M. Lipid profile during antihypertensive treatment. The SLIP Study Group: Study on Lipids with Isoptin Press. Drugs 1993; 46 (Suppl. 2): S.16–S.23.
38. Rosei E, Dal Palu C, Leonetti G et al. Clinical results of the Verapamil in Hypertension and Atherosclerosis Study (VHAS). J Hypertension 1997; 15: 1337–44.
39. Echizen H, Eichelbaum M. Clinical Pharmacokinetics of verapamil, nifedipine and diltiazem. Clin Pharmacokinetics 1986; 11: 425–49.
________________________________________________
2. Furberg CD, Psaty BM, Meyer JV. Nifedipine: Dose-related increase in mortality in patients with coronary heart disease. Circulation 1995; 92 (5): 1326–31.
3. Lee SH, Yu WC, Cheng JJ et al. Effect of verapamil on long-term tachycardia – induced atrial electrical remodeling. Circulation 2000; 101: 200–6.
4. Leistad E, Alknes G, Verburg E et al. Atrial contractile dysfunction after short-term atrial fibrillation is reduced by verapamil but increased by BAY K 8644. Circulation 1996; 93: 1736–54.
5. Lefrandt JD, Heitmann J, Sevre K et al. The effects of dihydropyridine and phenylalkylamine calcium antagonist classes on autonomic function in hypertension: the VAMPHYRE study. Am J Hypertens 2001; 14: 1083–9.
6. Harris DCH, Hammond WS, Bure TJ et al. Verapamil protects against progression of experimental chronic renal failure. Kidney Int 1987; 31: 41–6.
7. Bacris GZ, Copley JB, Vicknair N et al. Verapamil SR has similar nephroprotective properties to lisinopril and is significantly better in comparison to atenolol. Kidney International 1996; 50: 1641–59.
8. Stadler P, Leonardi L, Riesen W et al. Cardiovascular effects of verapamil in essential hypertension. Clin Pharmacol Ther 1987; 42: 485–92.
9. Speders S, Sosna J, Schumacher A et al. Efficacy and tolerability of Isoptin SR in essential hypertension. Hochdruck 1988; 8: 3–14.
10. EVEREST’H – Evaluation of Verapamil for Efficacy, Safety and Tolerability in the management of Hypertension. Multicentre trial of the antihypertensive efficacy and safety of Verapamil SR. Act Med Int 1990; 2: 3–7.
11. Kukes V.G., Krasnykh L.M., Teplonogova E.V. Primenenie Izoptina SR v lechenii arterial'noi gipertonii. Klin. farmakologiia i terapiia. 1999; 8: 51–2. [in Russian]
12. Grossman E, Messerli FH. Effect of calcium antagonists on plasma norepinerhrine levels, heart rate and blood pressure. Am J Cardiol 1997; 80: 1453–8.
13. Zachariah P, Sheps S, Oshrain C et al. Antihypertensive efficacy of sustained-release verapamil. J Clin Hypertens 1987; 3: 536–46.
14. Speders S, Sosna J, Schumacher A et al. Efficacy and safety of verapamil SR 240 mg in essential hypertension: results of a multicentric phase IV study. J Cardiovasc Pharmacol 1989; 13 (Suppl. 4): S.47–S.49.
15. Cummings JM, Amadlio P, Nelson L. The role of calcium channel blocker in the treatment of essential hypertension. Arch Intern Med 1991; 151: 250–9.
16. Makolkin V.I. Izoptin SR 240 – effektivnyi antigipertenzivnyi i antiishemicheskii preparat. Arterial'naia gipertenziia. 2006; 3: 233–6. [in Russian]
17. Hla K, Henry J, Latham A. Pharmacokinetics and pharmacodynamics of two formulations of verapamil. Br J Clin Pharmacol 1987; 24: 661–4.
18. Weinberger MH. The relationship of sodium balance and concomitant diuretic therapy to blood pressure response with calcium channel entry blockers. Am J Med 1991; 90 (Suppl. 5A): S.15–S.20.
19. Weir M, Lavin P. Comparison of the efficacy and tolerability of lisinopril and sustained – release verapamil in older patients with hypertension. Clin Ther 1991; 13 (3): 401–8.
20. Rubio-Guerra AF, Vargas-Robles H, Vargas-Ayala G et al. The effect of trandolapril and its fixed-dose combination with verapamil on circulating adhesion molecules levels in hypertensive patients with type 2 diabetes. Clin Exp Hypertens 2008; 30 (7): 685–8.
21. Manukian A.V., Sidorenkova N.B., Lavrent'ev A.V. Vliianie prolongirovannykh antagonistov kal'tsiia na tsirkadiannyi i ul'tradiannyi ritmy arterial'nogo davleniia bol'nykh s arterial'noi gipertoniei vysokogo riska. Farmakologiia. 2006; 7 (9): 228–35. [in Russian]
22. Schmieder RE, Messerli FH, Garavaglia GE et al. Cardiovascular effects of verapamil in patients with essential hypertension. Circulation 1987; 75 (5): 1030–6.
23. Granier P, Douste-Blazy M, Tredez P et al. Improvement in left ventricular hypertrophy and left ventricular diastolic function following verapamil therapy in mild to moderate hypertension. Eur J Clin Pharmacol 1990; 39 (Suppl. 1): S.45–S.46.
24. Van Merode T, Van Bortel L, Smeets FA et al. The effect of verapamil on carotid artery distensability and cross-sectional compliance in hypertensive patients. J Cardiovase Pharmacol 1990; 1: 109–13.
25. Breithaupt-Grogler K, Gerhardt G, Lehmann G et al. Blood pressure and aortic elastic properties-verapamil SR/trandolapril compared a metoprolol/hydrochlorothiazide combination therapy. Int J Clin Pharm Ther 1998; 36: 425–31.
26. Ferrari R, Cuchtnt K, Bobgneti R et al. How do calcium antagonists differ in clinical practice? Cardiovasc Drug Therapy 1994; 8 (Suppl. 3): S.566–S.575.
27. Pepine C, Handberg E, Cooper-De-Hoff R et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): A Randomized Controlled Trial. JAMA 2003; 290: 2805–16.
28. Pallone NM. Effect of calcium antagonists in the treatment of silent ischemic heart disease. Curr Ther Res 1989; 45: 339–46.
29. Rehnqvist N, Hjemdahl P, Billing E et al. Effect of metoprolol vs verapamil in patients with stable angina pectoris. The Angina Prognosis Study in Stockholm (APSIS). Eur Heart J 1996; 17: 76–81.
30. The Danish Verapamil Infarction Trial II – DAVIT II: Effect of verapamil on mortality and maior events after acute myocardial infarction. Am J Cardiol 1990; 66: 331–401.
31. Rengo F, Carbonin P, Pahor M et al. A controlled Trial of verapamil inpatients after acute myocardial infarction: results of the Calcium Antagonist Reinfarction Italian Study (CRIS). Am J Cardiol 1996; 77: 365–9.
32. Hoberg E, Dietz R, Frees U et al. Verapamil treatment after coronary angioplasty in patients at high risk of recurrent stenosis. Br Heart J 1994; 71: 254–60.
33. Zadionchenko V.S., Adasheva T.V., Zhilova E.V. i soavt. Kliniko-funktsional'nye osobennosti arterial'noi gipertonii u bol'nykh khronicheskim obstruktivnym zabolevaniem legkikh. RMZh. 2003; 9: 535–8. [in Russian]
34. Dvoretskii L.I. Klinicheskie rekomendatsii po vedeniiu bol'nykh KhOBL v sochetanii s arterial'noi gipertoniei i drugoi patologiei. RMZh. 2005; 13: 672–5. [in Russian]
35. Karpov Iu.A., Sorokin E.V. Osobennosti lecheniia arterial'noi gipertonii pri khronicheskikh obstruktivnykh zabolevaniiakh legkikh. RMZh. 2003; 19: 1048–51. [in Russian]
36. Andersson D, Rojdmark S. Improvement of glucose tolerance by verapamil in patients with non-insulin-dependent diabetes mellitus. Acta Med Scand 1981; 210 (1–2): 27–33.
37. Libretti A, Catalano M. Lipid profile during antihypertensive treatment. The SLIP Study Group: Study on Lipids with Isoptin Press. Drugs 1993; 46 (Suppl. 2): S.16–S.23.
38. Rosei E, Dal Palu C, Leonetti G et al. Clinical results of the Verapamil in Hypertension and Atherosclerosis Study (VHAS). J Hypertension 1997; 15: 1337–44.
39. Echizen H, Eichelbaum M. Clinical Pharmacokinetics of verapamil, nifedipine and diltiazem. Clin Pharmacokinetics 1986; 11: 425–49.
Авторы
Н.И.Гапонова*, В.Р.Абдрахманов
ФГБОУ ВО Московский государственный медико-стоматологический университет им. А.И.Евдокимова Минздрава России. 127473, Россия, Москва, ул. Делегатская, д. 20, стр. 1
*nade-gaponova@yandex.ru
A.I.Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of the Russian Federation. 127473, Russian Federation, Moscow, ul. Delegatskaia, d. 20, str. 1
*nade-gaponova@yandex.ru
ФГБОУ ВО Московский государственный медико-стоматологический университет им. А.И.Евдокимова Минздрава России. 127473, Россия, Москва, ул. Делегатская, д. 20, стр. 1
*nade-gaponova@yandex.ru
________________________________________________
A.I.Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of the Russian Federation. 127473, Russian Federation, Moscow, ul. Delegatskaia, d. 20, str. 1
*nade-gaponova@yandex.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.